WO2011067189A3 - Cmet-inhibitoren zur behandlung der endometriose - Google Patents

Cmet-inhibitoren zur behandlung der endometriose Download PDF

Info

Publication number
WO2011067189A3
WO2011067189A3 PCT/EP2010/068361 EP2010068361W WO2011067189A3 WO 2011067189 A3 WO2011067189 A3 WO 2011067189A3 EP 2010068361 W EP2010068361 W EP 2010068361W WO 2011067189 A3 WO2011067189 A3 WO 2011067189A3
Authority
WO
WIPO (PCT)
Prior art keywords
cmet inhibitors
treating endometriosis
endometriosis
cmet
inhibitors
Prior art date
Application number
PCT/EP2010/068361
Other languages
English (en)
French (fr)
Other versions
WO2011067189A2 (de
Inventor
Markus Koch
Frank Sacher
Oliver Martin Fischer
Thomas Zollner
Ulrike Fuhrmann
Martin Michels
Alexandros Vakalopoulos
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of WO2011067189A2 publication Critical patent/WO2011067189A2/de
Publication of WO2011067189A3 publication Critical patent/WO2011067189A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Behandlung der Endometriose mit cMet- Inhibitoren und cMet-lnhibitoren enthaltende Arzneimittel zur Behandlung der Endometriose.
PCT/EP2010/068361 2009-12-03 2010-11-29 Cmet-inhibitoren zur behandlung der endometriose WO2011067189A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009056886.7 2009-12-03
DE102009056886A DE102009056886A1 (de) 2009-12-03 2009-12-03 cMet-Inhibitoren zur Behandlung der Endometriose

Publications (2)

Publication Number Publication Date
WO2011067189A2 WO2011067189A2 (de) 2011-06-09
WO2011067189A3 true WO2011067189A3 (de) 2012-04-19

Family

ID=43969453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/068361 WO2011067189A2 (de) 2009-12-03 2010-11-29 Cmet-inhibitoren zur behandlung der endometriose

Country Status (2)

Country Link
DE (1) DE102009056886A1 (de)
WO (1) WO2011067189A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500277A (ja) 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
US20150147274A1 (en) 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met
WO2007075567A1 (en) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007132308A1 (en) * 2006-05-11 2007-11-22 Pfizer Products Inc. Triazolopyrazine derivatives useful as anti-cancer agents
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
WO2008071451A1 (en) * 2006-12-14 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors
WO2009007390A2 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
WO2009149836A1 (en) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Annellated 4- (indazolyl) -1,4-dihydropyridine derivatives and methods of use thereof
WO2011042368A1 (en) * 2009-10-06 2011-04-14 Bayer Schering Pharma Aktiengesellschaft Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635977A (en) 1969-11-03 1972-01-18 American Cyanamid Co Certain 6-trifluoromethylcytosines and thiocytosines their synthesis and their use in the synthesis of uracisls and thiouracil
ES2077591T3 (es) 1989-01-26 1995-12-01 Bayer Ag Derivados de acido (met)acrilico opticamente activos, su fabricacion, su polimerizacion para dar polimeros opticamente activos y su uso.
DE19546136A1 (de) 1995-12-11 1997-06-12 Bayer Ag Chirale stationäre Phasen für die chromatographische Trennung von optischen Isomeren
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
ES2466818T3 (es) 2003-09-26 2014-06-11 Exelixis, Inc. Moduladores c-Met y métodos de uso
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
KR100869393B1 (ko) 2004-08-26 2008-11-21 화이자 인코포레이티드 단백질 키나제 억제제로서 피라졸-치환된 아미노헤테로아릴화합물
ME01788B (me) 2004-08-26 2011-02-28 Pfizer Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
CA2603748A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met
WO2007075567A1 (en) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007132308A1 (en) * 2006-05-11 2007-11-22 Pfizer Products Inc. Triazolopyrazine derivatives useful as anti-cancer agents
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
WO2008071451A1 (en) * 2006-12-14 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors
WO2009007390A2 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
WO2009149836A1 (en) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Annellated 4- (indazolyl) -1,4-dihydropyridine derivatives and methods of use thereof
WO2011042368A1 (en) * 2009-10-06 2011-04-14 Bayer Schering Pharma Aktiengesellschaft Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDER JOSEPH PAUL ET AL: "Novel therapeutic inhibitors of the c-Met signaling pathway in cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 15, no. 7, 1 April 2009 (2009-04-01), pages 2207 - 2214, XP002592604, ISSN: 1078-0432, DOI: 10.1158/1078/-0432.CCR-08-1306 *
VERCELLINI ET AL: "Endometriosis: current and future medical therapies", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL OBSTETRICS ANDGYNAECOLOGY, BAILLIERE TINDALL, LONDON, GB, vol. 22, no. 2, 26 November 2007 (2007-11-26), pages 275 - 306, XP022491867, ISSN: 1521-6934, DOI: 10.1016/J.BPOBGYN.2007.10.001 *
YOSHIDA SOUICHI ET AL: "Hepatocyte growth factor/Met system promotes endometrial and endometriotic stromal cell invasion via autocrine and paracrine pathways.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 89, no. 2, February 2004 (2004-02-01), pages 823 - 832, XP002669733, ISSN: 0021-972X *

Also Published As

Publication number Publication date
DE102009056886A1 (de) 2011-06-09
WO2011067189A2 (de) 2011-06-09

Similar Documents

Publication Publication Date Title
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
WO2012062925A3 (en) Compounds and methods for treating pain
AP2011005901A0 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections.
WO2011130302A3 (en) Method of treating obesity using antioxidant inflammation modulators
EP2485798A4 (de) Vorrichtungen, systeme und verfahren zur behandlung neuropsychiatrischer erkrankungen
MX2011002966A (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
HK1179531A1 (en) Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis
EP2337535A4 (de) Systeme, vorrichtungen und verfahren zur behandlung von tinnitus
WO2012058211A3 (en) Quinazoline derivatives, compositions, and uses related thereto
WO2009129246A3 (en) Compositions and methods for preparing and using same
EP2385831A4 (de) Kleinmolekulare hemmer von nads, namnat und nmnat
EP2729464B8 (de) Cyclopropyl-kondensierte-1,3-thiazepine als bace 1- und/oder bace-2-hemmer
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2012017321A3 (en) Treatment for dyslipidemia
WO2011098778A3 (en) Peptides for vaccines against birch allergy
WO2013106460A3 (en) Compositions and methods for treating malignant astrocytomas
GB2554624B (en) Process for the Treatment of Ashes and Digestates, Treated Ashes and Digestates thus obtained and uses thereof.
EP2790721B8 (de) Fragmente von nicht-acyliertem ghrelin zur verwendung zur behandlung von prader-willi syndrom
EP3406242B8 (de) Tlr4 antagonist zur behandlung von erhöhten plasma ammoniak werten
WO2011029639A3 (en) Compounds and methods for treating neoplasia
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
EP2488507A4 (de) Neue mek-hemmer zur behandlung von diabetes
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10781716

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10781716

Country of ref document: EP

Kind code of ref document: A2